HIF1A and hepatocellular carcinoma: For example, combining radiotherapy with metabolic inhibitors (e.g., glycolysis-targeting agents), hypoxia-targeting drugs (e.g., HIF-1α inhibitors), and immunotherapy presents promising avenues for addressing HCC radioresistance.